Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001196001 | SCV001366429 | uncertain significance | Hypertrophic cardiomyopathy 14 | 2019-02-14 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. The following ACMG criteria were applied in classifying this variant: PP3. |
Labcorp Genetics |
RCV001196001 | SCV002408048 | benign | Hypertrophic cardiomyopathy 14 | 2023-05-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001726448 | SCV002504286 | likely benign | not provided | 2018-09-10 | criteria provided, single submitter | clinical testing | See Variant Classification Assertion Criteria. |
Ambry Genetics | RCV002436769 | SCV002747460 | likely benign | Cardiovascular phenotype | 2022-05-27 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Clinical Genetics, |
RCV001701304 | SCV001917592 | benign | not specified | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV001726448 | SCV001962844 | likely benign | not provided | no assertion criteria provided | clinical testing |